Trials / Active Not Recruiting
Active Not RecruitingNCT06568042
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 450 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3848575 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2024-08-22
- Primary completion
- 2026-06-01
- Completion
- 2026-09-01
- First posted
- 2024-08-23
- Last updated
- 2025-12-18
Locations
76 sites across 7 countries: United States, Canada, Germany, Japan, Mexico, Poland, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06568042. Inclusion in this directory is not an endorsement.